Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Proof of Concept, Open-Label, Randomized-Controlled Trial Evaluating the Efficacy and Safety of PARAGON Novel Metabolic Regulator Formula (PNMR) in the Management of Long COVID

NCT07627815 is registered in ClinicalTrials.gov with ParagonClinicals Inc. as lead sponsor.

NCT NCT07627815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07627815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Proof of Concept, Open-Label, Randomized-Controlled Trial Evaluating the Efficacy and Safety of PARAGON Novel Metabolic Regulator Formula (PNMR) in the Management of Long COVID
Lead sponsor
ParagonClinicals Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2026
Completion date
December 26, 2026
Enrollment
82 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

long covid